Pyruvate Potential Effects on Covid-19 Virus Infection: Novel Fluid Intervention and Prevention

Numerous experimental studies demonstrated that Pyruvate is more beneficial than anions in current fluids due to its beneficial biological and pharmacological properties via increasing hypoxia/anoxia tolerance, correcting hypoxic lactic acidosis and exerting anti-oxidative stress, which target against major features of pathological defects in Covid-19 viral infection: hypoxia and cytokine storm. These characteristics indicate that pyruvate is robustly systemic metabolism and multiorgan function protective in critical care patients with or without Covid-19 viral infection. Albeit it is not an anti-virus agent, studies suggest that pyruvate potentially facilitate anti-virus drugs, cytokine IL-6 blockers and interferons against Covid-19 and even inhibit virus replication as chloroquine treated Covid-19. Despite of not FDA-approved, many pyruvate clinical studies with several hundred patients subjected to various diseases strongly support its clinical effectiveness and safety. Currently, pyruvate is a nutritional supplement in markets. It is proposed in this review that compassionate uses of pyruvate-enriched intravenous and oral rehydration solutions are encouraged in intervention and prophylaxis of Covid-19 viral infection.

Article file ID not found.

The authors declare no conflict of interest.

Not applicable

The datasets used in this study are openly available at [repository link] and the source code is available on GitHub at [GitHub link].

This work did not receive any external funding.